The Korean Society of Pediatric Hematology-Oncology surveyed pediatric allogeneic hematopoietic stem cell transplantation in Korea. From 1983 to April 2000, 267 children underwent allogeneic hematopoietic stem cell transplantation. Seventy-nine children were transplanted for acute myelogenous leukemia (AML), 76 for severe aplastic anemia (SAA), 62 for acute lymphoblastic leukemia (ALL), 44 for chronic myelogenous leukemia/myelodysplastic syndrome (CML/MDS) and 11 for nonmalignant rare disease. There were 152 males and 115 females with a median age of 9 years and median follow-up of 25 months. One hundred and eighty-nine of 267 cases were HLA-matched sibling transplants. The estimated event-free survival (EFS) of patients with SAA who underwent HLA-matched sibling transplants is 89%. The estimated EFS of ALL in CR1 and CR2 are 77% and 67%, respectively. The estimated EFS of AML in CR1 and CR2 are 73% and 60%, respectively. The estimated EFS of AML in CR1 prepared with Bu/Cy is 82%. The estimated EFS of CML/MDS is 71%. Eight out of 10 children with nonmalignant rare disease who underwent HLA-matched transplants are alive with disease free. Thirty-three children underwent unrelated bone marrow transplantation and 17 cord blood transplantation. Outcomes of patients with alternative stem cell sources are not estimated due to short median follow-up. These data shows that allogeneic hematopoietic stem cell transplantation is a curative method for children with hematopoietic stem cell disorders and we wish to share these results.